Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q16611
UPID:
BAK_HUMAN
Alternative names:
Apoptosis regulator BAK; Bcl-2-like protein 7
Alternative UPACC:
Q16611; C0H5Y7; Q6I9T6; Q92533
Background:
The Bcl-2 homologous antagonist/killer, also known as Apoptosis regulator BAK or Bcl-2-like protein 7, plays a pivotal role in the mitochondrial apoptotic process. It promotes mitochondrial outer membrane permeabilization by forming pores, releasing apoptogenic factors like cytochrome c into the cytosol. This activation of caspase 9 leads to the activation of effector caspases, crucial for cell death.
Therapeutic significance:
Understanding the role of Bcl-2 homologous antagonist/killer could open doors to potential therapeutic strategies.